Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trial Research
Research from Queen's University broadens understanding of clinical trial research
May 18th, 2008
According to a study from Kingston, Canada, " Because the appropriate design and end points for phase II evaluation of targeted anticancer agents are unclear, we undertook a review of recent reports of phase II trials of targeted agents to determine the types of designs used, the planned end points, the outcomes, and the relationship between trial outcomes and regulatory approval. We retrieved reports of single-agent phase II trials in six solid tumors for 19 targeted drugs." "For each, we abstracted data regarding planned design and actual results. Response rates were examined for any relationship to eventual success of the agents, as determined by US Food and Drug...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
